Events

Building on the momentum of the first World Anti-Counterfeit Day (WACD) webinar – which brought together regulators to address the growing threat of falsified and substandard health products – Kenya’s health sector reconvened on June 16, 2026, to take the dialogue a step further. Hosted by the KAPI – Industry Alliance of Health Products and […]

KAPI – Industry Alliance of Health Products and Technologies – convened regulators, industry players and healthcare professionals on 9th June 2026 for the first session of its World Anti-Counterfeit Day Webinar Series, focused on strengthening Kenya’s response to falsified and substandard health products. Held virtually under the theme “Strengthening Partnerships to Combat Falsified and Substandard

On September 17th, KAPI reaffirmed its unwavering commitment to patient safety, focusing on the critical theme “Safe care for every newborn and child” for World Patient Safety Day 2025. Recognizing the unique vulnerabilities of pediatric and neonatal patients, KAPI launched a comprehensive initiative to raise awareness, educate, and drive meaningful change in healthcare safety.  The

Regulatory reliance is the act whereby the regulatory authority in one jurisdiction takes into account and gives significant weight to assessments performed by another regulatory authority or trusted institution, or to any other authoritative information, in reaching its own decision. The relying authority remains independent, responsible, and accountable for the decisions taken, even when it relies

On Tuesday 26th January 2021 the Kenya Association of Pharmaceutical Industry (KAPI) executive board led by the Chairperson, Willy Soriney paid a courtesy visit to the Principal Secretary, Ministry of Health Madam Susan Mochache. This was part of the associations’ stakeholder engagement mechanisms aimed at fostering collaborative spirit for the advancement of the health agenda for

As a membership organization driven by tenets of social responsibility and commitment to public health, in the wake of COVID-19 it is in our purview to drive a common agenda to flatten the curve of transmission, build concerted efforts to ensure uninterrupted supply of medicines, diagnostics and healthcare technologies. Additionally, our member companies have been

The Kenya Association of Pharmaceutical Industry (KAPI) has expressed its commitment to continue facilitating a progressive reduction in the cost of Non communicable diseases (NCDs) medicines locally. In a swift response to a public call by President Uhuru Kenyatta to international pharmaceutical firms, to reduce the cost of NCD medicines, KAPI, has confirmed ongoing efforts